Glucagon-like peptide-1 receptor agonists (GLP-1 RA) act by binding to and activating the GLP-1 receptor, resulting in glucose dependent increase in insulin secretion and decrease secretion of glucagon, so they are effective in decreasing blood glucose levels associated with reduced risk of hypoglycemia. This evidence concerns the gene GLP1R and Hypoglycemia.